Question:

Which of the following is given to treat thrombocytopenia secondary to myelosuppressive therapy?

Show Hint

Look for the platelet growth factor, not a red-cell or antifibrinolytic agent.
Updated On: Jun 24, 2026
  • Iron dextran
  • Oprelvekin (interleukin-11)
  • Tranexamic acid
  • Erythropoietin
Show Solution
collegedunia
Verified By Collegedunia

The Correct Option is B

Solution and Explanation

Step 1: Identify the requirement. The question asks for an agent that raises the platelet count after chemotherapy-induced (myelosuppressive) thrombocytopenia, i.e. a thrombopoietic growth factor.
Step 2: Oprelvekin is recombinant interleukin-11. It stimulates megakaryocyte maturation and platelet production, and is specifically approved to prevent severe thrombocytopenia after myelosuppressive chemotherapy.
Step 3: Eliminate the distractors. Iron dextran corrects iron deficiency anaemia, not platelet counts. Tranexamic acid is an antifibrinolytic that reduces bleeding but does not raise platelets. Erythropoietin stimulates red cell production, addressing anaemia, not thrombocytopenia.
Step 4: Hence the correct answer is oprelvekin (interleukin-11), option B.
Was this answer helpful?
0
0